Recently, Tang Xiuwen, Chairman and President Yunnan Wenshan Daphne Pharmaceutical Co., Ltd., took home from Beijing a golden placard saying the People's Republic of China GMP Certificate for Drug Products. This marks the first GMP-compliant pharmaceutical enterprise in the Yunnan province certified by a state drug certification center since establishment of China FDA, and Daphne's production and quality management complying with the national-level standard and in line with the international practice.
GMP as drug production and quality management guideline for pharmaceutical enterprises, has reportedly been implemented for over 30 years in the world and for over 10 years in China. Very few pharmaceutical enterprises have obtained GMP certificates. The Wenshan Daphne Pharmaceutical Company was just established in 1994. Tang Xiuwen, Chairman and President of the company, introduced GMP management practice. In stead of the restrictions caused by lack of capital, qualified persons, technology, equipment and production premises, they invested over RMB 13 million yuan in reconstruction of the comprehensive drug workshop and extraction workshop, addition of advanced equipment, improvement of plant environment, normalization of the operating procedures, and enhancement of the personal quality of the staff. The enterprise ever sent 160 employees to Kunming, Chengdu, Nanjing and Beijing to learn drug production, inspection, management, maintenance and marketing. Training has been provided for the staff, involving over 4000 participations. Many homegrown technical talents have grown to key persons of the enterprise. Early this April, the enterprise passed certification by state regulator for GMP compliance, jumping onto the list of modern enterprises. 
The Daphne Co. bases its business on panax pseudoginseng, a unique resource in Wenshan, from the very beginning. They have made tremendous effort in development of panax pseudoginseng products. Under guidance of the product development strategy of "relying on technology, eyeing the market, and producing a generation of products while developing & conceptually designing new generations, they have formed the advantages in product lineup covering unique or superior items from low to high and from crude to fine. When it comes to product research, the enterprise takes a "two-track" approach. They have established a panax pseudoginseng scientific research and new product development base in Kunming. Many high-power technical persons have been absorbed. This move has accelerated the development of panax pseudoginseng products. Last year, Daphne brought out tablets and injection powder using monomer extracted from tPNS, marking the panax pseudoginseng R&D reaching a sophisticated level. As the first ever products of their kinds in China, these two items have been listed in the provincial "Torch Programme" and "18 Key Projects". On May 17 this year, Daphne was certified by the Yunnan Provincial Committee of Science & Technology as a high-tech enterprise. So far, Daphne owns 59 drugs approved by the state regulator for sale, including 17 panax pseudoginseng series products, which contribute 95% of the enterprise's total sales. Last year, the enterprise posted total sales of over RMB 40 million yuan, with total assets hitting RMB 50 million yuan, being a leading private enterprise of the Wenshan Zhuang & Miao Autonomous Prefecture. 
Jan. 16, 2006  Daphne Pharmaceutical (Group) Co., Ltd. Yunnan